- Home
- EOI vs CMPX Comparison
EOI vs CMPX Comparison
Compare EOI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOI
- CMPX
- Stock Information
- Founded
- EOI 2004
- CMPX 2014
- Country
- EOI United States
- CMPX United States
- Employees
- EOI N/A
- CMPX N/A
- Industry
- EOI Finance/Investors Services
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- EOI Finance
- CMPX Health Care
- Exchange
- EOI Nasdaq
- CMPX Nasdaq
- Market Cap
- EOI 835.4M
- CMPX 730.9M
- IPO Year
- EOI N/A
- CMPX N/A
- Fundamental
- Price
- EOI $20.81
- CMPX $4.05
- Analyst Decision
- EOI
- CMPX Strong Buy
- Analyst Count
- EOI 0
- CMPX 7
- Target Price
- EOI N/A
- CMPX $14.71
- AVG Volume (30 Days)
- EOI 83.6K
- CMPX 1.8M
- Earning Date
- EOI 01-01-0001
- CMPX 11-10-2025
- Dividend Yield
- EOI 7.19%
- CMPX N/A
- EPS Growth
- EOI N/A
- CMPX N/A
- EPS
- EOI N/A
- CMPX N/A
- Revenue
- EOI N/A
- CMPX N/A
- Revenue This Year
- EOI N/A
- CMPX N/A
- Revenue Next Year
- EOI N/A
- CMPX N/A
- P/E Ratio
- EOI N/A
- CMPX N/A
- Revenue Growth
- EOI N/A
- CMPX N/A
- 52 Week Low
- EOI $14.36
- CMPX $1.27
- 52 Week High
- EOI $18.88
- CMPX $4.86
- Technical
- Relative Strength Index (RSI)
- EOI 52.12
- CMPX 52.79
- Support Level
- EOI $20.30
- CMPX $3.86
- Resistance Level
- EOI $21.10
- CMPX $4.27
- Average True Range (ATR)
- EOI 0.31
- CMPX 0.29
- MACD
- EOI 0.04
- CMPX -0.05
- Stochastic Oscillator
- EOI 77.59
- CMPX 18.51
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.